Inflammopharmacology

Canagliflozin reduces Parkinson’s symptoms and may affect gut inflammation and brain communication in rats

Updated

Abstract

Canagliflozin (CANA) treatment improved motor function and neuronal integrity in a rat model of Parkinson's disease.

  • Rotenone (ROT) administration caused significant motor impairments and dopaminergic neuronal loss in rats.
  • CANA treatment led to enhanced motor function and reduced α-synuclein accumulation in the brain.
  • ROT exposure altered gut microbiota composition, increasing Parabacteroides and Ruminococcaceae while depleting Prevotella-related taxa.
  • CANA restored gut microbial balance and decreased levels of lipopolysaccharide (LPS) leakage, mitigating systemic inflammation.
  • The findings indicate that CANA may protect against neurodegeneration in Parkinson's disease by modulating the gut-inflammasome-brain axis.

Simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free